Patent · US Active

Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides

US8609613B2 · kind B2 · utility

35Cited by

38References

20Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Yan Chen · Foster City, US
Elena Getmanova · Lexington, US
Martin C. Wright · Belmont, US
Alan S. Harris · Andover, US
Ai Ching Lim · Redwood City, US
Jochem Gokemeijer · Wayland, US
Lin Sun · Dedham, US
Michael Wittekind · Bainbridge Island, US

Key dates

Filing date	Jul 18, 2012
Grant date	Dec 17, 2013
Priority date	—
Expiry date	Jul 18, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/43
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.